Mumbai, Aug. 13 -- The approval covers strengths of 2.5 mg, 10 mg, 15 mg, and 20 mg. The approved tablets are bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Xarelto Tablets, manufactured by Janssen Pharmaceuticals, Inc.

The product will be manufactured at Indoco's facility in Verna Industrial Area, Goa (L-14, Verna, Goa - 403722).

Rivaroxaban is an oral anticoagulant used for the treatment and prevention of venous thromboembolism (VTE) - a serious condition involving blood clots in the veins, which can lead to complications such as pulmonary embolism.

Commenting on the development, Aditi Panandikar, managing director of Indoco Remedies, said, "Besides reflecting the capability of Indoco Remedies to del...